{
  "docId": "019de072-75de-708e-aad9-55788df6c953",
  "docSlug": "5188528054c3088b6a98b04815eb3ce3",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 40,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "Includes ASCO 2022 conference branding and clinical trial abbreviations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-75de-708e-aad9-55788df6c953/15",
  "deckHref": "/decks/019de072-75de-708e-aad9-55788df6c953",
  "deckJsonHref": "/decks/019de072-75de-708e-aad9-55788df6c953.json",
  "deckAnchorHref": "/decks/019de072-75de-708e-aad9-55788df6c953#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.3,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "HER2-low = human epidermal growth factor receptor 2 low; PFS = progression free survival; OS = overall survival; FDA = Food and Drug Administration; BTD = breakthrough therapy designation; RTOR = real-time oncology review; NSCLC = non small cell lung cancer; HER2mut = HER2-mutant; m = months; BC = breast cancer; reg. = regulatory; 3L = third line; 2L = second line.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2718a17c-966c-42dc-8517-0ff23b357d1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.28,
        "y": 0.6
      },
      "kind": "list",
      "text": "DESTINY-Lung01: Robust and durable anti-cancer activity in previously treated HER2-mut NSCLC; Median PFS: 8.2m, Median OS: 17.8m; US FDA BTD granted in 2020; US Priority Review granted in April 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0788fdfe-37c8-45cd-8a32-d4eec8e2d3ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.28,
        "y": 0.25
      },
      "kind": "list",
      "text": "DESTINY-Breast04: Statistically significant and clinically meaningful improvement in both PFS and OS; Efficacy in HER2-low patients regardless of HR status; US FDA BTD, RTOR granted in April 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e7f2979-2dba-4209-9e8b-deedef8ec62a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.25,
        "x": 0.7,
        "y": 0.25
      },
      "kind": "list",
      "text": "Upcoming news flow: HER2-low BC 3L+ (DB04) | full results; HER2+ BC 2L (DB03) | reg. decision; HER2-low BC 3L+ (DB04) | reg. submission; HER2-low 2L BC (DB06) | data readout; HER2-mut NSCLC (DL01) | reg. decision",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b788652-2e7f-44e9-b176-d5f407a6800f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.65,
        "x": 0.31,
        "y": 0.05
      },
      "kind": "title",
      "text": "New frontiers for Enhertu in HER2-low breast cancer and HER2-mut lung cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8f3b75c-c3c7-4bbd-bc9b-b304313f4443",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "9033f2c1-0a31-4be1-9e9e-1cfab54f34ea",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The slides showcase the company's achievements in Oncology, BioPharmaceuticals, and Rare Disease",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}